Discovery Labs' Proprietary Aerosol Drug Delivery Technology Showcased at the International Society for Aerosols in Medicine Annual Meeting

Discovery Laboratories, Inc. DSCO today announced that scientific data relating to the Company's proprietary aerosolization technology platform was presented at the 2011 International Society for Aerosols in Medicine (ISAM) Annual Meeting. The annual ISAM congress brings together experts in the biotechnology and medical technology industries along with academic thought leaders dedicated to all aspects of aerosol research in medicine. The presented non-clinical study was titled, 'Combined Delivery of CPAP and Aerosols to Premature Infants via a Novel Ventilator Circuit Adapter' and was authored by Dr. Mazela, et al. The objective of this study was to test a series of proprietary patient adaptors designed to effectively interface with conventional ventilation technologies to optimize delivery of aerosolized medications for patients requiring positive pressure ventilator support. The investigators concluded that the novel patient interface significantly reduced gas dilution when administered during CPAP respiratory support without increasing flow resistance, potentially improving aerosolized drug delivery to patients receiving positive pressure ventilator support. Dr. Thomas F. Miller, Chief Operating Officer of Discovery Labs, commented, "We are excited that these important data were accepted for presentation at ISAM, as this meeting is the most important international venue for new aerosolization technologies. While remaining focused on our Surfaxin® Complete Response submission target for the third quarter 2011, we have meaningfully advanced our aerosolization technology to support our Aerosurf® program. Dr. Mazela's study highlights the novelty of our proprietary patient interface technology, a key component of our vision for efficient aerosolized drug delivery for patients requiring positive pressure ventilation support. We are actively exploring the commercial utility and potential of this important new technology for broad pediatric and adult critical care applications."